Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
Key Points
To examine the relationship between histological subtypes and treatment response in non-small cell lung cancer patients.
Analyzed the response of NSCC-NOS subtype to PD-1/PD-L1 inhibitors
Compared outcomes with and without chemotherapy
NSCC-NOS subtype shows high responsiveness to first-line PD-1/PD-L1 inhibitors
Patient outcomes improve notably with NSCC-NOS when treated with immune checkpoint inhibitors
Abstract
NSCC-NOS is a histological subtype that is highly responsive to first-line PD-1/PD-L1 inhibitors with or without chemotherapy.
Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors | Synapse